Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.

Chang SC, Galea CA, Leung EW, Tajhya RB, Beeton C, Pennington MW, Norton RS.

Toxicon. 2012 Oct;60(5):840-50. doi: 10.1016/j.toxicon.2012.05.017. Epub 2012 May 31.


The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS.

J Biol Chem. 2008 Jan 11;283(2):988-97. Epub 2007 Nov 5.


N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS.

FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294. Epub 2015 Apr 23.


A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS.

FEBS Lett. 2012 Nov 16;586(22):3996-4001. doi: 10.1016/j.febslet.2012.09.038. Epub 2012 Oct 9.


Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.


Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13942-7.


Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.

Norton RS, Pennington MW, Wulff H.

Curr Med Chem. 2004 Dec;11(23):3041-52. Review.


Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.


Designed peptide analogues of the potassium channel blocker ShK toxin.

Lanigan MD, Pennington MW, Lefievre Y, Rauer H, Norton RS.

Biochemistry. 2001 Dec 25;40(51):15528-37.


Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.

Pennington MW, Lanigan MD, Kalman K, Mahnir VM, Rauer H, McVaugh CT, Behm D, Donaldson D, Chandy KG, Kem WR, Norton RS.

Biochemistry. 1999 Nov 2;38(44):14549-58.


Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.

Middleton RE, Sanchez M, Linde AR, Bugianesi RM, Dai G, Felix JP, Koprak SL, Staruch MJ, Bruguera M, Cox R, Ghosh A, Hwang J, Jones S, Kohler M, Slaughter RS, McManus OB, Kaczorowski GJ, Garcia ML.

Biochemistry. 2003 Nov 25;42(46):13698-707.


Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.


Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.

Pennington MW, Byrnes ME, Zaydenberg I, Khaytin I, de Chastonay J, Krafte DS, Hill R, Mahnir VM, Volberg WA, Gorczyca W, et al.

Int J Pept Protein Res. 1995 Nov;46(5):354-8.


Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG.

FASEB J. 2014 Sep;28(9):3952-64. doi: 10.1096/fj.14-251967. Epub 2014 Jun 2.


Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.

Lanigan MD, Kalman K, Lefievre Y, Pennington MW, Chandy KG, Norton RS.

Biochemistry. 2002 Oct 8;41(40):11963-71.


Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.

Pennington MW, Mahnir VM, Krafte DS, Zaydenberg I, Byrnes ME, Khaytin I, Crowley K, Kem WR.

Biochem Biophys Res Commun. 1996 Feb 27;219(3):696-701.


A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.

Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG.

J Biol Chem. 2003 Mar 14;278(11):9928-37. Epub 2003 Jan 2.


A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor.

Harvey AJ, Gable RW, Baell JB.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3193-6.


Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.

Tudor JE, Pennington MW, Norton RS.

Eur J Biochem. 1998 Jan 15;251(1-2):133-41.

Items per page

Supplemental Content

Write to the Help Desk